BidaskClub Upgrades NxStage Medical (NXTM) to Hold
NxStage Medical (NASDAQ:NXTM) was upgraded by stock analysts at BidaskClub from a “sell” rating to a “hold” rating in a research note issued to investors on Tuesday.
A number of other analysts have also issued reports on the stock. Zacks Investment Research lowered shares of NxStage Medical from a “hold” rating to a “sell” rating in a research report on Saturday, August 11th. ValuEngine lowered shares of NxStage Medical from a “buy” rating to a “hold” rating in a research report on Tuesday, August 7th. One analyst has rated the stock with a sell rating and four have given a hold rating to the company. The company has a consensus rating of “Hold” and an average price target of $30.00.
NASDAQ NXTM opened at $28.32 on Tuesday. The company has a market capitalization of $1.86 billion, a PE ratio of -128.73 and a beta of -0.04. NxStage Medical has a 52-week low of $22.70 and a 52-week high of $28.75.
About NxStage Medical
NxStage Medical, Inc, a medical technology company, develops, manufactures, and markets products and services for patients suffering from chronic or acute kidney failure. Its primary product includes the System One, a portable hemodialysis system, which is used primarily for home hemodialysis and a range of dialysis therapies to deliver in the home setting.
Receive News & Ratings for NxStage Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical and related companies with MarketBeat.com's FREE daily email newsletter.